Secondary Logo

Journal Logo

Original Article

Citrulline Malate Enhances Athletic Anaerobic Performance and Relieves Muscle Soreness

Pérez-Guisado, Joaquín1; Jakeman, Philip M2

Author Information
Journal of Strength and Conditioning Research: May 2010 - Volume 24 - Issue 5 - p 1215-1222
doi: 10.1519/JSC.0b013e3181cb28e0
  • Free



Anutritional supplement that enhances exercise capacity is said to have an ergogenic effect. The proposed or advertised ergogenic effect of many supplements is based on a presumptive metabolic pathway and may not necessarily translate to quantifiable changes in a variable as broadly defined as exercise performance. In Spain, citrulline malate (CM) is a popular sports supplement despite the fact that it is a pharmaceutical drug only authorized for the treatment of asthenia (under the brand name Stimol), of which the recommended dose is 1 g 3 times a day. Nevertheless, it is said that the best consumption pattern as an ergogenic aid is to intake a single dose of 4-10 g of CM just 1 hour before the sport session. Whether CM intake really improves performance has not been appropriately established, although sportsmen seeking higher performance and fast recovery after intensive training seem convinced that it does. For that reason we found CM to be a fascinating research subject and decided to investigate the presumptive metabolic pathway of CM and to establish whether CM really improves exercise performance.

The accumulation of lactic acid has long been considered an essential element in the phenomena of muscular fatigue (10). More recently, several studies have shown the close connection between the accumulation of ammonia in blood and tissue and the blockage of cellular energetic processes (3,11). Moreover, nitric oxide (NO) regulates many physiological functions of skeletal muscle (13). In connection with these concepts, the potential use of CM as an ergogenic aid should be based on 3 hypothetical mechanisms of action:

  1. The excess availability of citrulline, 1 of the amino acids of the ureogenesis cycle, enables, via the mass action law, acceleration of the rotation of this cycle and thereby facilitates the clearance of ammonium. Ammonium is an important fatigue factor because its intracellular accumulation stimulates glycolysis, while blocking the aerobic utilization of pyruvate but also its recycling in the direction of neoglucogenesis. This results in deviation of energy metabolism toward the exclusive formation of lactate (14).
  2. Malate, a metabolic intermediate of the Krebs cycle, is capable of behaving as a metabolic shuttle between cytoplasm and mitochondria, enables bypassing of blockade of the oxidative pathway induced by ammonia, and hence limits accumulation of lactic acid by reorienting it toward pyruvate genesis and its aerobic utilization or neoglucogenesis. Accumulation of lactate and resultant acidosis leads secondarily to the blockage of glycolysis (14).
  3. NO regulates many physiological functions of skeletal muscle including glucose uptake and oxidation, mitochondriogenesis, contractile functions, blood flow and fatty acid oxidation, and muscle repair through satellite cell activation and the release of myotrophic factors (13).

NO is synthesized by nitric oxide synthase, which utilizes l-arginine as substrate and produces l-citrulline as the second reaction product. l-arginine can be synthesized from l-citrulline providing a recycling pathway for the conversion of l-citrulline to NO via l-arginine (9). Moreover, comparing oral citrulline and oral arginine intakes, oral citrulline is a more efficient way of increasing body arginine levels (6,12).

The activity and excellent safety/acceptability of CM for the asthenia have been confirmed in 2 double-blind, placebo-controlled trials (5,7). Nevertheless, few studies have examined the ergogenic potential of CM to enhance resistance exercise performance in humans. Although the precise mechanism of action is, as yet, unknown, the purported ergogenic property of CM is probably linked to the following known actions:

  1. In a microbial model, malate accelerated ammonium clearance and citrulline facilitated lactate metabolism. These results suggest a synergistic action of the complex (2).
  2. In both animal and human models, results showed that CM stimulates hepatic ureogenesis and favors renal bicarbonate reabsorption. These metabolic actions confer a protective effect against acidosis and ammonia poisoning and may explain the fatigue-resistant property of CM in humans (4).

As a supplement, CM has been proven to be effective in athletic performance in very few studies:

  1. In a rat model, resistance to fatigue (it was quantified by measuring tension production during repetitive electrical stimulation of the isolated epitrochlearis muscle) was improved after treatment with CM (8).
  2. In humans, the effect of supplementation with 6 g of CM a day for 15 days found that CM led to a significant reduction in the sensation of fatigue, a 34% increase in the rate of oxidative adenosine triphosphate (ATP) production during exercise (finger flexions-recovery protocol), and a 20% increase in the rate of phosphocreatine recovery after exercise. They concluded that CM acts to promote aerobic energy production (1).

On the assumption that CM increases NO production and reduces the muscular fatigue through the reduction of lactic acid and ammonia in blood and tissue and that anaerobic exercise produces high levels of such metabolic wastes, we hypothesized that CM might be an ergogenic aid for an anaerobic exercise such as the flat barbell bench press. The purpose of the present study was to determine the effect of a single dose of CM (8 g) on the following:

  1. Performance in an anaerobic exercise of a high intensity comprising repeated sets of flat barbell bench press.
  2. Muscle soreness measured 24 and 48 hours following the high-intensity exercise bout.


Experimental Approach to the Problem

This study was conducted in 6 gyms across Andalusia (south of Spain). The subjects participated in 1 familiarization session and 2 identical testing sessions. During the familiarization session 1 repetition maximum (1RM) strength test in weight training for the flat barbell bench press was determined. Participants ingested CM (8 g) or placebo (2-period crossover design) 1 hour before the testing workout. The subjects' resistance was tested using the reps-to-fatigue test, at 80% of their predetermined 1 repetition maximum (RM), in the 8 sets of flat barbell bench presses during the pectoral workout session (4 sets at the beginning of the pectoral workout and 4 sets at the end). The effect of CM on muscle soreness 24 and 48 hours after the pectoral workout was tested using a self-reported soreness score (scale from 1 to 5).

During the familiarization session (the week before the study period), informed consent statements were signed, medical and exercise history forms were completed, and 1 repetition maximum (1RM) strength test in weight training for the flat barbell bench press was determined. The subjects participated in 1 familiarization session and 2 identical testing sessions.

The training program consisted of 5 workouts per week (from Monday to Friday) distributed as follows: Monday for chest, Tuesday for back, Wednesday for legs, Thursday for shoulders, and Friday for arms. Saturday and Sunday were resting days. Subjects rested for 48 hours before the testing day (Monday). The training program was the same during the 2-week study period (the same weight, exercises, sets, and reps). The length of washout between treatments was 1 week. The pectoral workout protocol (Figure 1) comprised 16 sets in the following order: 4 sets of flat barbell bench presses (80% 1RM weight for the flat bench press), 4 sets of incline barbell bench presses (80% 1RM weight for the flat bench press), 4 sets of incline flys (60% 1RM weight for the flat bench press), and 4 sets of flat barbell bench presses (80% 1RM weight for the flat bench press). The speed of each rep was 3-4 seconds (1-2 for the positive and 1-2 for the negative). Workout sessions were always at the same time for each person but not necessarily between subjects. All subjects were required to perform each exercise to the point at which that they reached muscular failure at the last repetition of each set. Subjects were instructed to rest for 1 minute between sets and for 2 minutes between each exercise. All workouts were completed at the participant's own training facility.

Figure 1
Figure 1:
Pectoral workout protocol.

Prior to testing, subjects were instructed to eat the same food in the same order over the 2-week study period and not to consume caffeinated beverages on the testing days and during the 2 days beforehand.


To participate in this study, subjects had to sign statements indicating that they were currently training >3 hours per week with a program that included the bench press and pectoral exercises; agree to follow a predetermined workout program; refrain from participating in any sporting activity throughout the entire study; have not used anabolic steroids either now or in the past; have not ingested creatine, HMB, thermogenics, or ergogenic levels of any nutritional supplements for an 8-week period and have not taken any nutritional supplements or nonprescription drugs during the study; do not have any existing medical conditions that would compromise their participation in the study; and avoid any changes in their usual diet.

This study was carried out throughout February-March in 41 healthy men whose mean weight was 81.12 ± 17.43 kg and mean age was 29.80 ± 7.64 years. They were recruited from 6 gyms. These gyms are located in 3 cities of the south of Spain (Cordoba, Granada, and Almeria). All subjects were free from chronic diseases, were not regularly taking prescription medications, were not taking any ergogenic aids, and had never taken CM supplements before. Moreover, all the subjects had participated in strength-training workouts over at least the previous 6 months and were physically active and thoroughly familiar with the pectoral workout protocol. Subjects had been training during the previous 6 months for an average of 6 ± 2 hours/week and 4 ± 2 workouts per week. The study was approved by the University of Cordoba human research ethics committee, and written informed consent was obtained from all participants before data collection.


The study was performed using a randomized, double-blind, 2-period crossover design. In a double-blind manner, subjects were randomly assigned a 200-mL CM beverage (80-mL CM solution; 8 g CM, 8 Stimol sachets from Laboratorios Pérez Giménez, Spain), 20 mL lemon juice, 10 g powdered sugar, 60 mg sodium saccharine, and tap potable water until complete 200 mL of solution) or a 200-mL placebo beverage that was similar in appearance, smell, consistency, and taste (40 mL lemon juice, 10 g powdered sugar, 60 mg sodium saccharine, and tap potable water until complete 200 mL of solution). Both beverages were shaken until fully dissolved and served in disposable white plastic glasses. Subjects drank the beverage 1 hour before the testing workout. Subjects were instructed to report any possible side effects to the researchers and their compliance with the training and supplementation protocols. The investigator who made the beverages and the investigator who evaluated the subjects were different.

On the test day (Monday), 1 hour after consuming the beverage, subjects performed the reps-to-fatigue test at 80% of their predetermined 1RM for the 8 sets of flat barbell bench presses (S1-4: 4 sets at the beginning of the pectoral workout; S1'-4': 4 sets at the end of the pectoral workout). Sixteen measurements were taken for each subject (8 for the CM session day and 8 for the placebo session day).

The subjects self-reported their soreness 24 and 48 hours after the pectoral day testing on a scale from 1 to 5 as follows:

  1. No soreness.
  2. Minimal soreness with no impact on immediate training.
  3. Medium soreness with minimal impact on immediate training.
  4. High soreness with negative impact on immediate training.
  5. Maximum soreness with physical disability for immediate training.

Statistical Analyses

The number of repetitions for each set and the score for muscle soreness are expressed as mean ± standard error (Table 1). The incremental percentage for reps with CM compared with the placebo is expressed as Δ %, and the decremental percentage for muscle soreness with CM compared with the placebo is expressed as ▿%.

Table 1
Table 1:
Changes in the number of reps achieved when performing flat barbell bench presses and in the scores assigned for muscle soreness.

For quantitative variables (number of reps), the difference between placebo and CM in the number of repetitions performed on the sets of flat barbell bench presses (S1-4: 4 sets at the beginning of the pectoral workout; S1′-4′: 4 sets at the end of the pectoral workout) was analyzed by within-group factorial 2-way analysis of variance. Previously, the Kolmogorov-Smirnov and Shapiro-Wilk test were done for testing normality and the F-Snedecor test was done for the assumption of homoscedasticity. The effect of CM on muscle soreness score (24 and 48 hours after the pectoral workout) was analyzed by Wilcoxon signed-rank test. The p-value for responders and nonresponders for the number of repetitions for each set and the score for muscle soreness was calculated by using a Fisher's exact test for a 2 × 2 contingency table (Table 2). SPSS (version 12.0; Chicago, IL, USA) was the statistical software package used for all analyses. Significance was accepted at a probability of p ≤ 0.05.

Table 2
Table 2:
Percentage of response to the citrulline malate for each set and muscle soreness.


The ingestion of citrulline malate was tolerated well by the majority of subjects with only 6 subjects (15%) reporting stomach discomfort as a side effect following its ingestion.

The mean change in the number of repetitions and muscle soreness scores are shown in Table 1. The individual data, indicating the variability of responders and nonresponders to CM is illustrated in Table 2. The number of repetitions showed a significant increase from placebo treatment to CM treatment from the third set evaluated. This increase was positively correlated with the number of sets inside each group (group of sets 1-4 and group of sets 1′-4′), achieving 18% extra repetitions for S4 and 53% extra repetitions (Table 1) for the last set (S4′). The percentage of responders was 61% for S4 and 100% for the last set (Table 2).

Compared to placebo, the muscle soreness score at 24 and 48 hours postexercise was significantly lower in the CM trial, achieving equal decremental percentage value of 40% at each time point (Table 1). The percentage of responders at 24 and 48 hours postexercise (Table 2) was significantly equal (97.56% versus 90.24 %). Graphical individual responses are represented by bar graphs (Figures 2-9).

Figure 2
Figure 2:
Response for set 3.
Figure 3
Figure 3:
Response for set 4.
Figure 4
Figure 4:
Response for set 1.
Figure 5
Figure 5:
Response for set 2.
Figure 6
Figure 6:
Response for set 3.
Figure 7
Figure 7:
Response for set 4.
Figure 8
Figure 8:
Response for muscle soreness at 24 h.
Figure 9
Figure 9:
Response for muscle soreness at 48 h.


CM is reported to lead to a significant reduction in the sensation of fatigue by increasing the rate of oxidative ATP production during exercise and the rate of phosphocreatine recovery after exercise (1). Moreover, many Spanish sportsmen seeking higher performance and fast recovery after intensive training sessions seem convinced that a single dose (4-10 g) of CM 1 hour before the sport session is an effective ergogenic aid. The results from the present study are consistent with the known capacity of CM as a buffer to acidosis (4), hyperammonemia (2,4), and lactate accumulation (2). The results of the present study indicate that a single dose of CM may confer a training and/or performance benefit to athletes engaged in high-intensity anaerobic exercise carried out consecutively, such as strength training or sprint sessions that significantly engage anaerobic metabolism and result in increased lactate, ammonia, and acidosis. For these same reasons, it is likely that CM supplementation would be less effective in enhancing the performance of short aerobic exercises sessions, or anaerobic sessions with sufficient rest time or high enough intensity, where lower levels of acidosis, lactate, and ammonium production would occur. The ability of CM to buffer the effect of exercise-induced increase in acidosis, lactate, and ammonium may also partly explain our observation of a reduction in muscle soreness 24 and 48 hours postexercise. Thus, we can give scientific arguments to support the belief of many Spanish sportsmen founded on experience: The potential use of CM as an ergogenic aid.

Practical Applications

In light of these results, the use of CM might be useful to increase athletic performance in high-intensity anaerobic exercises with short rest times and to relieve postexercise muscle soreness. CM might be also very useful to athletes undergoing intensive preparation involving a high level of training or in competitive events. Nevertheless, further research is required to determine which sports or activities might be enhanced with CM.


1. Bendahan, D, Mattei, JP, Ghattas, B, Confort-Gouny, S, Le Guern, ME, and Cozzone, PJ. Citrulline/malate promotes aerobic energy production in human exercising muscle. Br J Sports Med 36: 282-289, 2002.
2. Briand, J, Blehaut, H, Calvayrac, R, and Laval-Martin, D. Use of a microbial model for the determination of drug effects on cell metabolism and energetics: study of citrulline-malate. Biopharm Drug Dispos 13: 1-22, 1992.
3. Bryla, J and Niedzeweicka, A. Relationship between pyruvate carboxylation and citrulline synthesis in rat liver mitochondria: The effect of ammonia and energy. Int J Biochem 10: 235-239, 1979.
4. Callis, A, Magnan De Bornier, B, Serrano, JJ, Bellet, H, and Saumade, R. Activity of citrulline malate on acid-base balance and blood ammonia and amino acid levels. Study in the animal and in man. Arzneimittelforschung 41: 660-663, 1991.
5. Carbasse, M. Essai randomisé en double aveugle contre placebo du malate de citrulline en gériatrie. Rev Gériatrie 10: 286-288, 1985.
6. Curis, E, Crenn, P, and Cynober, L. Citrulline and the gut. Curr Opin Clin Nutr Metab Care 10: 620-626, 2007.
7. Dahan, R and Caulin, C. Evaluation clinique des antiasthéniques. Thérapie 39: 547-652, 1984.
8. Goubel, F, Vanhoutte, C, Allaf, O, Verleye, M, and Gillardin, JM. Citrulline malate limits increase in muscle fatigue induced by bacterial endotoxins. Can J Physiol Pharmacol 75: 205-207, 1997.
9. Hayashi, T, Juliet, PA, Matsui-Hirai, H, Miyazaki, A, Fukatsu, A, Funami, J, Iguchi A, and Ignarro, LJ. l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits. Proc Natl Acad Sci USA 102: 13681-13686, 2005.
10. Hill, AV, Long, CNH, and Lupton, H. Muscular exercise, Lactic acid and the supply and utilization of oxygen. Parts I-III. Proc R Soc Lond 96: 438-478, 1924.
11. Lowenstein, JM. Ammonia production in muscles and other tissues: The purine nucleotide cycle. Physiol Rev 52: 382-414, 1972.
12. Osowska, S, Moinard, C, Neveux, N, Loi, C, and Cynober, L. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut 53: 1781-1786, 2004.
13. Petrovic, V, Buzadzic, B, Korac, A, Vasilijevic, A, Jankovic, A, Micunovic, K, and Korac, B. Antioxidative defence alterations in skeletal muscle during prolonged acclimation to cold: role of L-arginine/NO-producing pathway. J Exp Biol 211: 114-120, 2008.
14. Vanuxem, P, Vanuxem, D, Fomaris, E, and Bernasconi, P. The role of lactate and ammonium in fatigue. Gazette Medicale 7: 62-72, 1986.

anaerobic exercise; ergogenic aids; lactate; sport performance; sport supplements; weight training

© 2010 National Strength and Conditioning Association